Top Markets
#1 Nesa Nesa +337.53%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +17.01%
#4 Status Status +12.64%
#5 Wrapped NXM Wrapped NXM +7.23%
#6 Kinesis Silver Kinesis Silver +6.60%
#7 Venom Venom +5.81%
#8 Tornado Cash Tornado Cash +4.89%
#9 HOME HOME +4.80%
#10 Ontology Gas Ontology Gas +3.99%
Coin of the day
Nesa Nesa
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Xếp hạng trong cổ phiếu #20201
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Giá cổ phiếu
$10.25
Đồng bộ lần cuối: 2024-02-22
Vốn hóa thị trường
$137.83M
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
0.00%
Quốc gia
CN
Giao dịch Gracell Biotechnologies Inc. (GRCL)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Gracell Biotechnologies Inc. (GRCL)
Giá đóng cửa cao nhất: $10.24 vào 2024-02-01

Giá đóng cửa thấp nhất: $22.88 vào 2021-01-01
Lịch sử giá cổ phiếu của Gracell Biotechnologies Inc. từ 2021 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2024 60.59%
2023 155.25%
2022 -61.61%
2021 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.65 -12.25%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 7.33%
CH